Treatment regimens using anti-NKG2A antibodies
US12037392B2 · kind B2 · utility
0Cited by
17References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 2021 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Jan 18, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.